Search

everythinglearnresearchcommunity

for

Search:↓

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.

A woman developed severe bladder inflammation after cancer treatment with Cytoxan.

Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.

LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Flutamide rarely causes liver toxicity in prostate cancer patients.

A woman's adrenal tumor disappeared after treatment with cyproterone acetate.

Pexidartinib often causes liver issues and fatigue, especially in women.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

Bicalutamide improves hair density in women safely.

Bicalutamide may effectively treat female pattern hair loss with minimal side effects.

Kanglaite injection with chemotherapy improves treatment and reduces side effects for advanced lung cancer.

Cyproterone acetate and ethinylestradiol effectively reduce hirsutism and acne in women.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

LGD1069 effectively prevents breast tumors in mice without toxicity.

Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.

Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Mesotherapy with bicalutamide has limited effectiveness for female hair loss.

Flutamide helps with prostate cancer and some skin conditions but can harm the liver.